{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:09:37Z","timestamp":1788905377426,"version":"build-2803163510"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":248,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In clinical trials, harms (i.e., adverse events) are often reported by simply counting the number of people who experienced each event. Reporting only frequencies ignores other dimensions of the data that are important for stakeholders, including severity, seriousness, rate (recurrence), timing, and groups of related harms. Additionally, application of selection criteria to harms prevents most from being reported. Visualization of data could improve communication of multidimensional data. We replicated and compared the characteristics of 6 different approaches for visualizing harms: dot plot, stacked bar chart, volcano plot, heat map, treemap, and tendril plot. We considered binary events using individual participant data from a randomized trial of gabapentin for neuropathic pain. We assessed their value using a heuristic approach and a group of content experts. We produced all figures using R and share the open-source code on GitHub. Most original visualizations propose presenting individual harms (e.g., dizziness, somnolence) alone or alongside higher level (e.g., by body systems) summaries of harms, although they could be applied at either level. Visualizations can present different dimensions of all harms observed in trials. Except for the tendril plot, all other plots do not require individual participant data. The dot plot and volcano plot are favored as visualization approaches to present an overall summary of harms data. Our value assessment found the dot plot and volcano plot were favored by content experts. Using visualizations to report harms could improve communication. Trialists can use our provided code to easily implement these approaches.<\/jats:p>","DOI":"10.1093\/epirev\/mxac005","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T09:08:53Z","timestamp":1662455333000},"page":"55-66","source":"Crossref","is-referenced-by-count":8,"title":["Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials"],"prefix":"10.1093","volume":"44","author":[{"given":"Riaz","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Goerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Mayo-Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Golzarri-Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"McAdams DeMarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliseo","family":"Guallar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,18]]},"reference":[{"issue":"19","key":"2023020903111902700_ref1","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse events in randomized trials: neglected, restricted, distorted, and silenced","volume":"169","author":"Ioannidis","year":"2009","journal-title":"Arch Intern Med."},{"issue":"19","key":"2023020903111902700_ref2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Intern Med."},{"issue":"7","key":"2023020903111902700_ref3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066844","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review","volume":"8","author":"Dwan","year":"2013","journal-title":"PLoS One."},{"issue":"9","key":"2023020903111902700_ref4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002127","article-title":"Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review","volume":"13","author":"Golder","year":"2016","journal-title":"PLoS Med."},{"key":"2023020903111902700_ref5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6904-1-3","article-title":"Reporting of adverse drug reactions in randomised controlled trials - a systematic survey","volume":"1","author":"Loke","year":"2001","journal-title":"BMC Clin Pharmacol."},{"issue":"2","key":"2023020903111902700_ref6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp0808659","article-title":"The Neurontin legacy \u2014 marketing through misinformation and manipulation","volume":"360","author":"Landefeld","year":"2009","journal-title":"N Engl J Med."},{"issue":"10","key":"2023020903111902700_ref7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Improving patient care better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med."},{"issue":"6","key":"2023020903111902700_ref8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/2168479015587363","article-title":"Statistical considerations on the evaluation of imbalances of adverse events in randomized clinical trials","volume":"49","author":"Ma","year":"2015","journal-title":"Ther Innov Regul Sci."},{"key":"2023020903111902700_ref9","volume-title":"National Adverse Drug Reaction Directory: \u201cCOSTART\u201d (Coding Symbols for Thesaurus of Adverse Reaction Terms)","author":"USFood and Drug Administration","year":"1970"},{"key":"2023020903111902700_ref10","author":"International Conference on Harmonization","year":"2021"},{"issue":"5","key":"2023020903111902700_ref11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/08870449808407431","article-title":"Evaluating explanations about drug prescriptions: effects of varying the nature of information about side effects and its relative position in explanations","volume":"13","author":"Berry","year":"1998","journal-title":"Psychol Health."},{"issue":"1","key":"2023020903111902700_ref12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1472-6947-14-76","article-title":"Words or numbers? Communicating risk of adverse effects in written consumer health information: a systematic review and meta-analysis","volume":"14","author":"B\u00fcchter","year":"2014","journal-title":"BMC Med Inform Decis Mak."},{"issue":"3","key":"2023020903111902700_ref13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08870440290029520a","article-title":"Communicating information about medication side effects: effects on satisfaction, perceived risk to health, and intention to comply","volume":"17","author":"Berry","year":"2002","journal-title":"Psychol Health."},{"issue":"6","key":"2023020903111902700_ref14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00005650-199106000-00014","article-title":"Adverse drug effects and need for drug information","volume":"29","author":"Enlund","year":"1991","journal-title":"Med Care."},{"issue":"1","key":"2023020903111902700_ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12875-016-0408-0","article-title":"Patients\u2019 views of adverse events in primary and ambulatory care: a systematic review to assess methods and the content of what patients consider to be adverse events","volume":"17","author":"Lang","year":"2016","journal-title":"BMC Fam Pract."},{"issue":"9","key":"2023020903111902700_ref16","first-page":"483","article-title":"Advising patients about patient safety: current initiatives risk shifting responsibility","volume":"31","author":"Entwistle","year":"2005","journal-title":"Jt Comm J Qual Patient Saf."},{"issue":"6","key":"2023020903111902700_ref17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/intqhc\/mzi065","article-title":"Patient perspectives of patient-provider communication after adverse events","volume":"17","author":"Duclos","year":"2005","journal-title":"Int J Qual Health Care."},{"issue":"2","key":"2023020903111902700_ref18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s40267-014-0176-7","article-title":"Do physicians communicate the adverse effects of medications that older patients want to hear?","volume":"31","author":"Tarn","year":"2015","journal-title":"Drugs Ther Perspect."},{"issue":"10","key":"2023020903111902700_ref19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing patient voice in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med."},{"issue":"1","key":"2023020903111902700_ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200326010-00001","article-title":"Patients\u2019 understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales","volume":"26","author":"Berry","year":"2003","journal-title":"Drug Saf."},{"key":"2023020903111902700_ref21","first-page":"59","author":"Mcneal","year":"2010"},{"key":"2023020903111902700_ref22","first-page":"456","article-title":"An information-centric framework for designing patient-centered medical decision aids and risk communication","volume":"1","author":"Franklin","year":"2013","journal-title":"AMIA Annu Symp Proc."},{"issue":"1","key":"2023020903111902700_ref23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s13063-019-3581-3","article-title":"Opportunities for selective reporting of harms in randomized clinical trials: selection criteria for non-systematic adverse events","volume":"20","author":"Mayo-Wilson","year":"2019","journal-title":"Trials."},{"issue":"113","key":"2023020903111902700_ref24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.04.020","article-title":"Harms are assessed inconsistently and reported inadequately part 2: non-systematic adverse events","author":"Mayo-Wilson","year":"2019","journal-title":"J Clin Epidemiol."},{"issue":"113","key":"2023020903111902700_ref25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jclinepi.2019.04.022","article-title":"Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events","author":"Mayo-Wilson","year":"2019","journal-title":"J Clin Epidemiol."},{"issue":"86","key":"2023020903111902700_ref26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jclinepi.2017.05.007","article-title":"Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis","author":"Mayo-Wilson","year":"2017","journal-title":"J Clin Epidemiol."},{"issue":"91","key":"2023020903111902700_ref27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jclinepi.2017.07.014","article-title":"Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy","author":"Mayo-Wilson","year":"2017","journal-title":"J Clin Epidemiol."},{"key":"2023020903111902700_ref28","article-title":"Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level","volume":"368","author":"Wallach","year":"2020","journal-title":"BMJ."},{"key":"2023020903111902700_ref29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ."},{"issue":"31","key":"2023020903111902700_ref30","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/sim.5356","article-title":"A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews","author":"Kirkham","year":"2012","journal-title":"Stat Med."},{"key":"2023020903111902700_ref31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f7668","article-title":"Quality of reporting in systematic reviews of adverse events: systematic review","volume":"348","author":"Zorzela","year":"2014","journal-title":"BMJ."},{"key":"2023020903111902700_ref32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g6501","article-title":"Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews","volume":"349","author":"Saini","year":"2014","journal-title":"BMJ."},{"key":"2023020903111902700_ref33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jclinepi.2016.05.003","article-title":"Most systematic reviews of adverse effects did not include unpublished data","volume":"77","author":"Golder","year":"2016","journal-title":"J Clin Epidemiol."},{"issue":"3","key":"2023020903111902700_ref34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1037\/a0024850","article-title":"Numbers can be worth a thousand pictures: individual differences in understanding graphical and numerical representations of health-related information","volume":"31","author":"Gaissmaier","year":"2012","journal-title":"Health Psychol."},{"issue":"2","key":"2023020903111902700_ref35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jbi.2009.12.001","article-title":"Data visualization speeds review of potential adverse drug events in patients on multiple medications","volume":"43","author":"Duke","year":"2010","journal-title":"J Biomed Inform."},{"issue":"12","key":"2023020903111902700_ref36","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1109\/TVCG.2014.2346682","article-title":"DecisionFlow: visual analytics for high-dimensional temporal event sequence data","volume":"20","author":"Gotz","year":"2014","journal-title":"IEEE Trans Vis Comput Graph."},{"issue":"1","key":"2023020903111902700_ref37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1109\/TVCG.2016.2598588","article-title":"PROACT: iterative design of a patient-centered visualization for effective prostate cancer health risk communication","volume":"23","author":"Hakone","year":"2017","journal-title":"IEEE Trans Vis Comput Graph."},{"issue":"2","key":"2023020903111902700_ref38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1037\/a0014474","article-title":"Using icon arrays to communicate medical risks : overcoming low numeracy","volume":"28","author":"Galesic","year":"2009","journal-title":"Health Psychol."},{"issue":"1","key":"2023020903111902700_ref39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1186\/s13063-020-04903-0","article-title":"Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials","volume":"21","author":"Cornelius","year":"2020","journal-title":"Trials."},{"issue":"2","key":"2023020903111902700_ref40","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ."},{"key":"2023020903111902700_ref41","first-page":"274","article-title":"Interactive intervention analysis","volume":"2012","author":"Gotz","year":"2012","journal-title":"AMIA Annu Symp Proc."},{"key":"2023020903111902700_ref42","first-page":"439","volume-title":"CHI \u201813 Extended Abstracts on Human Factors in Computing Systems","author":"Perer","year":"2013"},{"key":"2023020903111902700_ref43","first-page":"133","volume-title":"ACM International Conference Proceeding Series","author":"Saket","year":"2016"},{"issue":"1","key":"2023020903111902700_ref44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1109\/TVCG.2018.2865146","article-title":"A heuristic approach to value-driven evaluation of visualizations","volume":"25","author":"Wall","year":"2019","journal-title":"IEEE Trans Vis Comput Graph."},{"key":"2023020903111902700_ref45","first-page":"46","volume-title":"ACM International Conference Proceeding Series","author":"Stasko","year":"2014"},{"issue":"1","key":"2023020903111902700_ref46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10543406.2013.736805","article-title":"The practice of pre-marketing safety assessment in drug development","volume":"23","author":"Chuang-Stein","year":"2013","journal-title":"J Biopharm Stat."},{"issue":"1","key":"2023020903111902700_ref47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pst.254","article-title":"Graphical approaches to the analysis of safety data from clinical trials","volume":"7","author":"Amit","year":"2008","journal-title":"Pharm Stat."},{"issue":"3","key":"2023020903111902700_ref48","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1740774513485311","article-title":"Summarizing the incidence of adverse events using volcano plots and time intervals","volume":"10","author":"Zink","year":"2013","journal-title":"Clin Trials."},{"issue":"2","key":"2023020903111902700_ref49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2168479017738980","article-title":"Sources of safety data and statistical strategies for design and analysis: clinical trials","volume":"52","author":"Zink","year":"2018","journal-title":"Ther Innov Regul Sci."},{"issue":"8","key":"2023020903111902700_ref50","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jamia\/ocy016","article-title":"The tendril plot-a novel visual summary of the incidence, significance and temporal aspects of adverse events in clinical trials","volume":"25","author":"Karpefors","year":"2018","journal-title":"J Am Med Inform Assoc."},{"issue":"1","key":"2023020903111902700_ref51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12874-020-01167-9","article-title":"Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy","volume":"20","author":"Phillips","year":"2020","journal-title":"BMC Med Res Methodol."},{"key":"2023020903111902700_ref52","first-page":"522","article-title":"Using treemaps to represent medical data","volume":"124","author":"Chazard","year":"2006","journal-title":"Stud Health Technol Inform."},{"issue":"2","key":"2023020903111902700_ref53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2168479017741112","article-title":"Sources of safety data and statistical strategies for design and analysis: postmarket surveillance","volume":"52","author":"Izem","year":"2018","journal-title":"Ther Innov Regul Sci."},{"key":"2023020903111902700_ref54","first-page":"237","volume-title":"Proceedings of the Workshop on Advanced Visual Interfaces AVI","author":"Mittelst\u00e4dt","year":"2014"},{"issue":"1","key":"2023020903111902700_ref55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40814-018-0284-6","article-title":"Methods to identify and prioritize patient-centered outcomes for use in comparative effectiveness research","volume":"4","author":"Mayo-Wilson","year":"2018","journal-title":"Pilot Feasibility Stud."},{"issue":"1","key":"2023020903111902700_ref56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001378","article-title":"Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin","volume":"10","author":"Vedula","year":"2013","journal-title":"PLoS Med."},{"issue":"20","key":"2023020903111902700_ref57","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use","volume":"361","author":"Vedula","year":"2009","journal-title":"N Engl J Med."},{"key":"2023020903111902700_ref58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-13-136","article-title":"Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin\u00ae litigation","volume":"13","author":"Vedula","year":"2012","journal-title":"Trials."},{"key":"2023020903111902700_ref59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jrsm.1277","article-title":"Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study)","volume":"9","author":"Mayo-Wilson","year":"2017","journal-title":"Res Synth Methods."},{"issue":"6","key":"2023020903111902700_ref60","article-title":"Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodologic investigation (protocol)","volume":"11","author":"Mayo-Wilson","year":"2021","journal-title":"BMJ."},{"key":"2023020903111902700_ref61","author":"Karpefors","year":"2020"},{"key":"2023020903111902700_ref62","author":"Wilkins","year":"2021"},{"key":"2023020903111902700_ref63","article-title":"Clinical adverse events data analysis and visualization [abstract PO10]","author":"Yeh","journal-title":"Presented at The Pharmaceutical Industry SAS Users Group Conference, June 3\u20136, 2007, Denver, Colorado"},{"issue":"2","key":"2023020903111902700_ref64","first-page":"377","article-title":"Recent advancements in the analysis and presentation of safety data","volume":"35","author":"Chuang-Stein","year":"2001","journal-title":"Ther Innov Regul Sci."},{"issue":"6","key":"2023020903111902700_ref65","article-title":"Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry","volume":"10","author":"Phillips","year":"2020","journal-title":"BMJ."},{"issue":"5","key":"2023020903111902700_ref66","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10543400903105463","article-title":"Statistical methods to analyze adverse events data of randomized clinical trials","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J Biopharm Stat."},{"issue":"62","key":"2023020903111902700_ref67","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jclinepi.2008.08.005","article-title":"Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials","author":"Tsang","year":"2009","journal-title":"J Clin Epidemiol."},{"issue":"60","key":"2023020903111902700_ref68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.0006-341X.2004.00186.x","article-title":"Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model","author":"Berry","year":"2004","journal-title":"Biometrics."},{"issue":"5","key":"2023020903111902700_ref69","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1006\/ijhc.2000.0422","article-title":"Empirical studies of information visualization: a meta-analysis","volume":"53","author":"Chen","year":"2000","journal-title":"Int J Hum Comput."},{"key":"2023020903111902700_ref70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1145\/989863.989880","article-title":"The challenge of information visualization evaluation","volume-title":"Proceedings of the Workshop on Advanced Visual Interfaces AVI","author":"Plaisant","year":"2004"},{"issue":"11","key":"2023020903111902700_ref71","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1109\/TVCG.2013.89","article-title":"The five Ws for information visualization with application to healthcare informatics","volume":"19","author":"Zhang","year":"2013","journal-title":"IEEE Trans Vis Comput Graph."},{"key":"2023020903111902700_ref72","volume-title":"Interactive Data Visualization of Adverse Events Clinical Trial Data with the D3.Js Script Library","author":"Laurent","year":"2014"},{"key":"2023020903111902700_ref73","volume-title":"Monitoring Adverse Events Using an Interactive Web-Based Tool Immune Tolerance Network (ITN)","author":"Bailey","year":"2015"},{"issue":"144","key":"2023020903111902700_ref74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jclinepi.2021.12.023","article-title":"Improving the analysis of adverse event data in randomised controlled trials","author":"Cornelius","year":"2022","journal-title":"J Clin Epidemiol."}],"container-title":["Epidemiologic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/epirev\/advance-article-pdf\/doi\/10.1093\/epirev\/mxac005\/46214015\/mxac005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/epirev\/article-pdf\/44\/1\/55\/49124655\/mxac005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/epirev\/article-pdf\/44\/1\/55\/49124655\/mxac005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T03:13:58Z","timestamp":1675912438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/epirev\/article\/44\/1\/55\/6692449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,18]]},"published-print":{"date-parts":[[2022,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/epirev\/mxac005","relation":{},"ISSN":["1478-6729"],"issn-type":[{"value":"1478-6729","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022]]},"published":{"date-parts":[[2022]]}}}